HomeCompareCGSM vs MRK

CGSM vs MRK: Dividend Comparison 2026

CGSM yields 3.06% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $32.4K in total portfolio value
10 years
CGSM
CGSM
● Live price
3.06%
Share price
$26.28
Annual div
$0.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.3K
Annual income
$373.31
Full CGSM calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CGSM vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCGSMMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CGSM + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CGSM pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CGSM
Annual income on $10K today (after 15% tax)
$260.47/yr
After 10yr DRIP, annual income (after tax)
$317.31/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,011.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CGSM + MRK for your $10,000?

CGSM: 50%MRK: 50%
100% MRK50/50100% CGSM
Portfolio after 10yr
$40.6K
Annual income
$5,085.72/yr
Blended yield
12.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CGSM
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CGSM buys
0
MRK buys
0
No recent congressional trades found for CGSM or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCGSMMRK
Forward yield3.06%2.76%
Annual dividend / share$0.81$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$24.3K$56.8K
Annual income after 10y$373.31$9,798.13
Total dividends collected$3.4K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CGSM vs MRK ($10,000, DRIP)

YearCGSM PortfolioCGSM Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,006$306.43$11,206$366.19$200.00MRK
2$12,092$315.21$12,650$502.35$558.00MRK
3$13,262$323.65$14,407$694.19$1.1KMRK
4$14,522$331.74$16,585$967.82$2.1KMRK
5$15,878$339.50$19,342$1,363.89$3.5KMRK
6$17,337$346.92$22,913$1,947.19$5.6KMRK
7$18,904$354.00$27,662$2,823.89$8.8KMRK
8$20,588$360.75$34,159$4,173.35$13.6KMRK
9$22,397$367.19$43,337$6,308.80$20.9KMRK
10$24,338$373.31$56,776$9,798.13$32.4KMRK

CGSM vs MRK: Complete Analysis 2026

CGSMStock

The fund's investment objective is to provide current income exempt from regular federal income tax, consistent with a short duration profile as described in the prospectus and with the preservation of capital.Distinguishing Characteristics The fund will invest at least 80% of its assets in bonds and other debt instruments, including municipal bonds, which are debt obligations that pay interest that is exempt from federal income taxation, with payments made from a wide variety of sources, including governmental revenue streams and private enterprises.The fund will maintain an average portfolio duration that is within 1 year of the average duration of the Bloomberg Municipal Short 1-5 Years Index.The fund will normally invest at least 80% of its assets in, or derive at least 80% of its income from, securities exempt from regular federal income tax. May invest up to 20% of its assets in bonds that fund private, for-profit organizations (also known as private activity bonds) whose interest is subject to the federal alternative minimum tax.

Full CGSM Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CGSM vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CGSM vs SCHDCGSM vs JEPICGSM vs OCGSM vs KOCGSM vs MAINCGSM vs JNJCGSM vs ABBVCGSM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.